{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T14:22:59Z","timestamp":1794579779323,"version":"4.9.1"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["88887.706252\/2022-00"],"award-info":[{"award-number":["88887.706252\/2022-00"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Local treatment of canine urothelial carcinoma (UC) of the bladder is a challenge. More than 90% of the cases invade the muscular layer, more than 50% develop on bladder sites with a difficult surgical approach and often requiring radical surgical procedures. This study aims to evaluate the safety and feasibility of electrochemotherapy (ECT) with intravenous bleomycin (BLM) as a local therapy for bladder UC. This prospective study included 21 dogs with spontaneous bladder UC. Regional\/distant metastases and neoplastic infiltration of the serosa was considered the main exclusion criteria. We had no deaths during ECT or in the immediate postoperative period, and no suture dehiscence. Most dogs (19\/21) developed mild adverse effects, whereas two dogs developed ureteral stenosis. Complete response (CR) was achieved in 62% of the cases (13\/21), while partial response (PR) was achieved in 24% (5\/21). The median survival and disease-free survival times were 284 and 270\u00a0days, respectively. Overall survival was significantly better in the dogs who achieved a CR. In conclusion, ECT was well-tolerated in dogs with UC, demonstrating its safety and feasibility. These data pave the way for new studies aimed at evaluating the effectiveness of ECT in canine bladder UC as a translational model for human disease.<\/jats:p>","DOI":"10.1038\/s41598-023-45433-4","type":"journal-article","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T13:02:57Z","timestamp":1701262977000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Evaluation of the safety and feasibility of electrochemotherapy with intravenous bleomycin as local treatment of bladder cancer in dogs"],"prefix":"10.1038","volume":"13","author":[{"given":"Marcelo Monte Mor","family":"Rangel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"La\u00eds Calazans Menescal","family":"Linhares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna Duro","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela Ota Hisayasu","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe Horacio","family":"Maglietti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrigo Barboza","family":"de Nardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,29]]},"reference":[{"key":"45433_CR1","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.3892\/ol.2018.8837","volume":"16","author":"S De Brot","year":"2018","unstructured":"De Brot, S. et al. The dog as an animal model for bladder and urethral urothelial carcinoma: Comparative epidemiology and histology. Oncol. Lett. 16, 1641\u20131649. https:\/\/doi.org\/10.3892\/ol.2018.8837 (2018).","journal-title":"Oncol. Lett."},{"key":"45433_CR2","volume-title":"TNM Classification of Tumours in Domestic Animals","author":"LN Owen","year":"1980","unstructured":"Owen, L. N. TNM Classification of Tumours in Domestic Animals (World Health Organization, 1980)."},{"key":"45433_CR3","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3233\/BLC-170145","volume":"4","author":"BC Sommer","year":"2018","unstructured":"Sommer, B. C., Dhawan, D., Ratliff, T. L. & Knapp, D. W. Naturally-occurring canine invasive urothelial carcinoma: A model for emerging therapies. Bladder Cancer 4, 149\u2013159. https:\/\/doi.org\/10.3233\/BLC-170145 (2018).","journal-title":"Bladder Cancer"},{"key":"45433_CR4","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.3389\/fonc.2019.01493","volume":"9","author":"DW Knapp","year":"2020","unstructured":"Knapp, D. W. et al. Naturally-occurring invasive urothelial carcinoma in dogs, a unique model to drive advances in managing muscle invasive bladder cancer in humans. Front. Oncol. 9, 1493. https:\/\/doi.org\/10.3389\/fonc.2019.01493 (2020).","journal-title":"Front. Oncol."},{"key":"45433_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S1078-1439(99)00006-X","volume":"5","author":"DW Knapp","year":"2000","unstructured":"Knapp, D. W. et al. Naturally-occurring canine transitional cell carcinoma of the urinary bladder a relevant model of human invasive bladder cancer. Urol. Oncol. 5, 47\u201359. https:\/\/doi.org\/10.1016\/S1078-1439(99)00006-X (2000).","journal-title":"Urol. Oncol."},{"key":"45433_CR6","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1111\/vco.12286","volume":"15","author":"SJ Marvel","year":"2017","unstructured":"Marvel, S. J., S\u00e9guin, B., Dailey, D. D. & Thamm, D. H. Clinical outcome of partial cystectomy for transitional cell carcinoma of the canine bladder. Vet. Comp. Oncol. 15, 1417\u20131427. https:\/\/doi.org\/10.1111\/vco.12286 (2017).","journal-title":"Vet. Comp. Oncol."},{"key":"45433_CR7","first-page":"572","volume-title":"Small Animal Clinical Oncology Withrow & MacEwen\u2019s","author":"CM Fulkerson","year":"2020","unstructured":"Fulkerson, C. M. & Knapp, D. W. Tumors of the urinary system. In Small Animal Clinical Oncology Withrow & MacEwen\u2019s 6th edn (eds Vail, D. M. et al.) 572\u2013582 (Elsevier, Saint Louis, 2020).","edition":"6"},{"key":"45433_CR8","first-page":"133","volume":"62","author":"ML Bradbury","year":"2021","unstructured":"Bradbury, M. L. et al. Clinical outcomes of dogs with transitional cell carcinoma receiving medical therapy, with and without partial cystectomy. Can. Vet. J. 62, 133 (2021).","journal-title":"Can. Vet. J."},{"key":"45433_CR9","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.rvsc.2010.05.015","volume":"90","author":"P Wongsetthachai","year":"2011","unstructured":"Wongsetthachai, P., Pramatwinai, C., Banlunara, W. & Kalpravidh, M. Urinary bladder wall substitution using autologous tunica vaginalis in male dogs. Res. Vet. Sci. 90, 156\u2013159. https:\/\/doi.org\/10.1016\/j.rvsc.2010.05.015 (2011).","journal-title":"Res. Vet. Sci."},{"key":"45433_CR10","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/j.1532-950X.2014.12104.x","volume":"43","author":"S Boston","year":"2014","unstructured":"Boston, S. & Singh, A. Total cystectomy for treatment of transitional cell carcinoma of the urethra and bladder trigone in a dog. Vet. Surg. 43, 294\u2013300. https:\/\/doi.org\/10.1111\/j.1532-950X.2014.12104.x (2014).","journal-title":"Vet. Surg."},{"key":"45433_CR11","first-page":"73","volume":"56","author":"K Saeki","year":"2015","unstructured":"Saeki, K., Fujita, A., Fujita, N., Nakagawa, T. & Nishimura, R. Total cystectomy and subsequent urinary diversion to the prepuce or vagina in dogs with transitional cell carcinoma of the trigone area: A report of 10 cases (2005\u20132011). Can. Vet. J. 56, 73 (2015).","journal-title":"Can. Vet. J."},{"key":"45433_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/vsu.12583","volume":"46","author":"R Ricardo Huppes","year":"2017","unstructured":"Ricardo Huppes, R. et al. Radical cystectomy and cutaneous ureterostomy in 4 dogs with trigonal transitional cell carcinoma: Description of technique and case series. Vet. Surg. 46, 111\u2013119. https:\/\/doi.org\/10.1111\/vsu.12583 (2017).","journal-title":"Vet. Surg."},{"key":"45433_CR13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1939-1676.1992.tb00330.x","volume":"6","author":"AM Norris","year":"1992","unstructured":"Norris, A. M. et al. Canine bladder and urethral tumors: A retrospective study of 115 cases (1980\u20131985). J. Vet. Intern. Med. 6, 145\u2013153. https:\/\/doi.org\/10.1111\/j.1939-1676.1992.tb00330.x (1992).","journal-title":"J. Vet. Intern. Med."},{"key":"45433_CR14","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/j.1748-5827.1996.tb01745.x","volume":"37","author":"EA Stone","year":"1996","unstructured":"Stone, E. A., George, T. F., Gilson, S. D. & Page, R. L. Partial cystectomy for urinary bladder neoplasia: Surgical technique and outcome in 11 dogs. J. Small Anim. Pract. 37, 480\u2013485. https:\/\/doi.org\/10.1111\/j.1748-5827.1996.tb01745.x (1996).","journal-title":"J. Small Anim. Pract."},{"key":"45433_CR15","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/j.1740-8261.1987.tb00053.x","volume":"28","author":"M Walker","year":"1987","unstructured":"Walker, M. & Breider, M. Intraoperative radiotherapy of canine bladder cancer. Vet. Radiol. 28, 200\u2013204. https:\/\/doi.org\/10.1111\/j.1740-8261.1987.tb00053.x (1987).","journal-title":"Vet. Radiol."},{"key":"45433_CR16","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/0360-3016(88)90016-8","volume":"14","author":"TJ Kinsella","year":"1988","unstructured":"Kinsella, T. J. et al. Tolerance of the canine bladder to intraoperative radiation therapy: An experimental study. Int. J. Radiat. Oncol. Biol. Phys. 14, 939\u2013946. https:\/\/doi.org\/10.1016\/0360-3016(88)90016-8 (1988).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"45433_CR17","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1740-8261.2002.tb01668.x","volume":"43","author":"CR Anderson","year":"2002","unstructured":"Anderson, C. R., McNiel, E. A., Gillette, E. L., Powers, B. E. & LaRue, S. M. Late complications of pelvic irradiation in 16 dogs. Vet. Radiol. Ultrasound 43, 187\u2013192. https:\/\/doi.org\/10.1111\/j.1740-8261.2002.tb01668.x (2002).","journal-title":"Vet. Radiol. Ultrasound"},{"key":"45433_CR18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.5326\/0400131","volume":"40","author":"VJ Poirier","year":"2004","unstructured":"Poirier, V. J., Forrest, L. J., Adams, W. M. & Vail, D. M. Piroxicam, mitoxantrone, and coarse fraction radiotherapy for the treatment of transitional cell carcinoma of the bladder in 10 dogs: A pilot study. J. Am. Anim. Hosp. Assoc. 40, 131\u2013136. https:\/\/doi.org\/10.5326\/0400131 (2004).","journal-title":"J. Am. Anim. Hosp. Assoc."},{"key":"45433_CR19","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/j.1939-1676.2012.00946.x","volume":"26","author":"MW Nolan","year":"2012","unstructured":"Nolan, M. W. et al. Intensity-modulated and image-guided radiation therapy for treatment of genitourinary carcinomas in dogs. J. Vet. Intern. Med. 26, 987\u2013995. https:\/\/doi.org\/10.1111\/j.1939-1676.2012.00946.x (2012).","journal-title":"J. Vet. Intern. Med."},{"key":"45433_CR20","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/vru.12339","volume":"57","author":"K Choy","year":"2016","unstructured":"Choy, K. & Fidel, J. Tolerability and tumor response of a novel low-dose palliative radiation therapy protocol in dogs with transitional cell carcinoma of the bladder and urethra. Vet. Radiol. Ultrasound 57, 341\u2013351. https:\/\/doi.org\/10.1111\/vru.12339 (2016).","journal-title":"Vet. Radiol. Ultrasound"},{"key":"45433_CR21","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/ilar\/ilu018","volume":"55","author":"DW Knapp","year":"2014","unstructured":"Knapp, D. W. et al. Urinary bladder cancer in dogs, a naturally occurring model for cancer biology and drug development. ILAR J. 55, 100\u2013118. https:\/\/doi.org\/10.1093\/ilar\/ilu018 (2014).","journal-title":"ILAR J."},{"key":"45433_CR22","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1158\/2326-6066.CIR-18-0751","volume":"7","author":"S Maeda","year":"2019","unstructured":"Maeda, S., Murakami, K., Inoue, A., Yonezawa, T. & Matsuki, N. CCR4 blockade depletes regulatory T cells and prolongs survival in a canine model of bladder cancer anti-treg immunotherapy for canine bladder cancer. Cancer Immunol. Res. 7, 1175\u20131187. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0751 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"45433_CR23","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1158\/1535-7163.MCT-20-0893","volume":"20","author":"P Rossman","year":"2021","unstructured":"Rossman, P. et al. Phase I\/II trial of Vemurafenib in dogs with naturally occurring, BRAF-mutated urothelial carcinoma BRAF inhibitor trial in dogs with naturally occurring cancer. Mol. Cancer Ther. 20, 2177\u20132188. https:\/\/doi.org\/10.1158\/1535-7163.MCT-20-0893 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"45433_CR24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41598-021-04229-0","volume":"12","author":"S Maeda","year":"2022","unstructured":"Maeda, S. et al. Lapatinib as first-line treatment for muscle-invasive urothelial carcinoma in dogs. Sci. Rep. 12, 4. https:\/\/doi.org\/10.1038\/s41598-021-04229-0 (2022).","journal-title":"Sci. Rep."},{"key":"45433_CR25","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","volume":"63","author":"M Burger","year":"2013","unstructured":"Burger, M. et al. Epidemiology and risk factors of urothelial bladder cancer. Eur. Urol. 63, 234\u2013241. https:\/\/doi.org\/10.1016\/j.eururo.2012.07.033 (2013).","journal-title":"Eur. Urol."},{"key":"45433_CR26","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester, R. J. et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 49, 466\u2013477. https:\/\/doi.org\/10.1016\/j.eururo.2005.12.031 (2006).","journal-title":"Eur. Urol."},{"key":"45433_CR27","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00345-018-2438-9","volume":"37","author":"LL Monteiro","year":"2019","unstructured":"Monteiro, L. L. et al. ICUD-SIU international consultation on bladder cancer 2017: Management of non-muscle invasive bladder cancer. World J. Urol. 37, 51\u201360. https:\/\/doi.org\/10.1007\/s00345-018-2438-9 (2019).","journal-title":"World J. Urol."},{"key":"45433_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/medsci8010015","volume":"8","author":"K Saginala","year":"2020","unstructured":"Saginala, K. et al. Epidemiology of bladder cancer. Med. Sci. 8, 15. https:\/\/doi.org\/10.3390\/medsci8010015 (2020).","journal-title":"Med. Sci."},{"key":"45433_CR29","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.3892\/ol.2015.2888","volume":"9","author":"N Zhang","year":"2015","unstructured":"Zhang, N., Li, D., Shao, J. & Wang, X. Animal models for bladder cancer: The model establishment and evaluation. Oncol. Lett. 9, 1515\u20131519. https:\/\/doi.org\/10.3892\/ol.2015.2888 (2015).","journal-title":"Oncol. Lett."},{"key":"45433_CR30","doi-asserted-by":"publisher","first-page":"57766","DOI":"10.18632\/oncotarget.17714","volume":"8","author":"BA John","year":"2017","unstructured":"John, B. A. & Said, N. Insights from animal models of bladder cancer: Recent advances, challenges, and opportunities. Oncotarget 8, 57766. https:\/\/doi.org\/10.18632\/oncotarget.17714 (2017).","journal-title":"Oncotarget"},{"key":"45433_CR31","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.3390\/biomedicines9101472","volume":"9","author":"MM Tsamouri","year":"2021","unstructured":"Tsamouri, M. M., Steele, T. M., Mudryj, M., Kent, M. S. & Ghosh, P. M. Comparative cancer cell signaling in muscle-invasive urothelial carcinoma of the bladder in dogs and humans. Biomedicines 9, 1472. https:\/\/doi.org\/10.3390\/biomedicines9101472 (2021).","journal-title":"Biomedicines"},{"key":"45433_CR32","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejcsup.2006.08.005","volume":"4","author":"LM Mir","year":"2006","unstructured":"Mir, L. M. Bases and rationale of the electrochemotherapy. Eur. J. Cancer Suppl. 4, 38\u201344. https:\/\/doi.org\/10.1016\/j.ejcsup.2006.08.005 (2006).","journal-title":"Eur. J. Cancer Suppl."},{"key":"45433_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2022.868989","author":"M Tellado","year":"2022","unstructured":"Tellado, M., Mir, L. M. & Maglietti, F. Veterinary guidelines for electrochemotherapy of superficial tumors. Front. Vet. Sci. https:\/\/doi.org\/10.3389\/fvets.2022.868989 (2022).","journal-title":"Front. Vet. Sci."},{"key":"45433_CR34","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ejcsup.2006.08.003","volume":"4","author":"LM Mir","year":"2006","unstructured":"Mir, L. M. et al. Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes. Eur. J. Cancer Suppl. 4, 14\u201325. https:\/\/doi.org\/10.1016\/j.ejcsup.2006.08.003 (2006).","journal-title":"Eur. J. Cancer Suppl."},{"key":"45433_CR35","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.cvsm.2019.04.006","volume":"49","author":"EP Spugnini","year":"2019","unstructured":"Spugnini, E. P. & Baldi, A. Electrochemotherapy in veterinary oncology: State-of-the-art and perspectives. Vet. Clin. Small Anim. Pract. 49, 967\u2013979. https:\/\/doi.org\/10.1016\/j.cvsm.2019.04.006 (2019).","journal-title":"Vet. Clin. Small Anim. Pract."},{"key":"45433_CR36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4067\/S0719-81322019000200045","volume":"51","author":"MM Rangel","year":"2019","unstructured":"Rangel, M. M. et al. Electrochemotherapy in the treatment of neoplasms in dogs and cats. Austral J. Vet. Sci. 51, 45\u201351. https:\/\/doi.org\/10.4067\/S0719-81322019000200045 (2019).","journal-title":"Austral J. Vet. Sci."},{"key":"45433_CR37","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1515\/raon-2017-0043","volume":"51","author":"F Maglietti","year":"2017","unstructured":"Maglietti, F., Tellado, M., Olaiz, N., Michinski, S. & Marshall, G. Minimally invasive electrochemotherapy procedure for treating nasal duct tumors in dogs using a single needle electrode. Radiol. Oncol. 51, 422\u2013430. https:\/\/doi.org\/10.1515\/raon-2017-0043 (2017).","journal-title":"Radiol. Oncol."},{"key":"45433_CR38","doi-asserted-by":"publisher","first-page":"100","DOI":"10.4314\/ovj.v11i1.15","volume":"11","author":"P Valenti","year":"2021","unstructured":"Valenti, P. et al. Evaluation of electrochemotherapy in the management of apocrine gland anal sac adenocarcinomas in dogs: A retrospective study. Open Vet. J. 11, 100\u2013106. https:\/\/doi.org\/10.4314\/ovj.v11i1.15 (2021).","journal-title":"Open Vet. J."},{"key":"45433_CR39","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3390\/vetsci8030053","volume":"8","author":"P Sim\u010di\u010d","year":"2021","unstructured":"Sim\u010di\u010d, P. et al. A retrospective multicentric study of electrochemotherapy in the treatment of feline nasal planum squamous cell carcinoma. Vet. Sci. 8, 53. https:\/\/doi.org\/10.3390\/vetsci8030053 (2021).","journal-title":"Vet. Sci."},{"key":"45433_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-017-1186-8","volume":"15","author":"G Di Monta","year":"2017","unstructured":"Di Monta, G. et al. Electrochemotherapy efficacy evaluation for treatment of locally advanced stage III cutaneous squamous cell carcinoma: A 22-cases retrospective analysis. J. Transl. Med. 15, 1\u20138. https:\/\/doi.org\/10.1186\/s12967-017-1186-8 (2017).","journal-title":"J. Transl. Med."},{"key":"45433_CR41","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.ejso.2019.11.509","volume":"46","author":"AJ Clover","year":"2020","unstructured":"Clover, A. J. et al. Electrochemotherapy for the treatment of primary basal cell carcinoma; a randomised control trial comparing electrochemotherapy and surgery with five year follow up. Eur. J. Surg. Oncol. 46, 847\u2013854. https:\/\/doi.org\/10.1016\/j.ejso.2019.11.509 (2020).","journal-title":"Eur. J. Surg. Oncol."},{"key":"45433_CR42","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.ijsu.2015.04.055","volume":"18","author":"V Granata","year":"2015","unstructured":"Granata, V. et al. Electrochemotherapy in locally advanced pancreatic cancer: Preliminary results. Int. J. Surg. 18, 230\u2013236. https:\/\/doi.org\/10.1016\/j.ijsu.2015.04.055 (2015).","journal-title":"Int. J. Surg."},{"key":"45433_CR43","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.ejso.2018.01.090","volume":"44","author":"M Djokic","year":"2018","unstructured":"Djokic, M. et al. Electrochemotherapy as treatment option for hepatocellular carcinoma, a prospective pilot study. Eur. J. Surg. Oncol. 44, 651\u2013657. https:\/\/doi.org\/10.1016\/j.ejso.2018.01.090 (2018).","journal-title":"Eur. J. Surg. Oncol."},{"key":"45433_CR44","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1620\/tjem.172.291","volume":"172","author":"O Yamaguchi","year":"1994","unstructured":"Yamaguchi, O. et al. Potentiation of antitumor effect of bleomycin by local electric pulses in mouse bladder tumor. Tohoku J. Exp. Med. 172, 291\u2013293. https:\/\/doi.org\/10.1620\/tjem.172.291 (1994).","journal-title":"Tohoku J. Exp. Med."},{"key":"45433_CR45","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s002800050539","volume":"39","author":"Y Kubota","year":"1996","unstructured":"Kubota, Y. et al. Electropermeabilization in bladder cancer chemotherapy. Cancer Chemother. Pharmacol. 39, 67\u201370. https:\/\/doi.org\/10.1007\/s002800050539 (1996).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"45433_CR46","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s002400000140","volume":"28","author":"M Ogihara","year":"2000","unstructured":"Ogihara, M. & Yamaguchi, O. Potentiation of effects of anticancer agents by local electric pulses in murine bladder cancer. Urol. Res. 28, 391\u2013397. https:\/\/doi.org\/10.1007\/s002400000140 (2000).","journal-title":"Urol. Res."},{"key":"45433_CR47","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/10717540260397864","volume":"9","author":"K Mitsui","year":"2002","unstructured":"Mitsui, K. et al. Effective treatment of bladder tumor-bearing mice by direct delivery of bleomycin using electrochemotherapy. Drug Deliv. 9, 249\u2013252. https:\/\/doi.org\/10.1080\/10717540260397864 (2002).","journal-title":"Drug Deliv."},{"key":"45433_CR48","doi-asserted-by":"publisher","first-page":"3","DOI":"10.26717\/BJSTR.2018.12.002221PDF","volume":"1","author":"MMM Rangel","year":"2018","unstructured":"Rangel, M. M. M., de Oliveira, K. D., Freytag, J. O., Quadros, P. G. & Suzuki, D. O. H. Electrochemotherapy on bladder-preliminary results. Biomed. J. Sci. Tech. Res. 1, 3. https:\/\/doi.org\/10.26717\/BJSTR.2018.12.002221PDF (2018).","journal-title":"Biomed. J. Sci. Tech. Res."},{"key":"45433_CR49","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/vco.12677","volume":"19","author":"AK LeBlanc","year":"2021","unstructured":"LeBlanc, A. K. et al. Veterinary cooperative oncology group\u2014Common terminology criteria for adverse events (VCOG-CTCAE v2) following investigational therapy in dogs and cats. Vet. Comp. Oncol. 19, 311\u2013352. https:\/\/doi.org\/10.1111\/vco.12677 (2021).","journal-title":"Vet. Comp. Oncol."},{"key":"45433_CR50","doi-asserted-by":"publisher","first-page":"289","DOI":"10.30466\/vrf.2020.113009.2688","volume":"11","author":"DS Dos Anjos","year":"2020","unstructured":"Dos Anjos, D. S. et al. Preliminary assessment of electrochemotherapy feasibility in dogs with vesical transitional cell carcinoma. Vet. Res. Forum 11, 289. https:\/\/doi.org\/10.30466\/vrf.2020.113009.2688 (2020).","journal-title":"Vet. Res. Forum"},{"key":"45433_CR51","doi-asserted-by":"publisher","first-page":"4727","DOI":"10.1016\/0006-2952(88)90344-9","volume":"37","author":"S Orlowski","year":"1988","unstructured":"Orlowski, S., Belehradek, J. Jr., Paoletti, C. & Mir, L. M. Transient electropermeabilization of cells in culture: Increase of the cytotoxicity of anticancer drugs. Biochem. Pharmacol. 37, 4727\u20134733. https:\/\/doi.org\/10.1016\/0006-2952(88)90344-9 (1988).","journal-title":"Biochem. Pharmacol."},{"key":"45433_CR52","first-page":"5462","volume":"53","author":"O Tounekti","year":"1993","unstructured":"Tounekti, O., Pron, G., Belehradek, J. Jr. & Mir, L. M. Bleomycin, an apoptosis-mimetic drug that induces two types of cell death depending on the number of molecules internalized. Cancer Res. 53, 5462\u20135469 (1993).","journal-title":"Cancer Res."},{"key":"45433_CR53","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1385\/1-59259-080-2:99","volume-title":"Electrochemotherapy Electrogenetherapy Transdermal Drug Delivery","author":"LM Mir","year":"2000","unstructured":"Mir, L. M. & Orlowski, S. The basis of electrochemotherapy. In Electrochemotherapy Electrogenetherapy Transdermal Drug Delivery (eds Jaroszeski, M. J. et al.) 99\u2013117 (Humana Press, 2000). https:\/\/doi.org\/10.1385\/1-59259-080-2:99."},{"key":"45433_CR54","doi-asserted-by":"publisher","first-page":"535","DOI":"10.5455\/OVJ.2021.v11.i4.3","volume":"11","author":"VM Govoni","year":"2021","unstructured":"Govoni, V. M. et al. Lymphatic invasion is a significant indicator of poor patient outcome in canine bladder urothelial carcinoma. Open Vet. J. 11, 535\u2013543. https:\/\/doi.org\/10.5455\/OVJ.2021.v11.i4.3 (2021).","journal-title":"Open Vet. J."},{"key":"45433_CR55","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.2460\/javma.238.8.1004","volume":"238","author":"L Marconato","year":"2011","unstructured":"Marconato, L. et al. Toxic effects and antitumor response of gemcitabine in combination with piroxicam treatment in dogs with transitional cell carcinoma of the urinary bladder. J. Am. Vet. Med. Assoc. 238, 1004\u20131010. https:\/\/doi.org\/10.2460\/javma.238.8.1004 (2011).","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"45433_CR56","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3233\/BLC-150044","volume":"2","author":"DW Knapp","year":"2016","unstructured":"Knapp, D. W. et al. A nonselective cyclooxygenase inhibitor enhances the activity of vinblastine in a naturally-occurring canine model of invasive urothelial carcinoma. Bladder Cancer 2, 241\u2013250. https:\/\/doi.org\/10.3233\/BLC-150044 (2016).","journal-title":"Bladder Cancer"},{"key":"45433_CR57","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1111\/jvim.12159","volume":"27","author":"SL Pace","year":"2013","unstructured":"Pace, S. L., Creevy, K. E., Krimer, P. M. & Brainard, B. M. Assessment of coagulation and potential biochemical markers for hypercoagulability in canine hyperadrenocorticism. J. Vet. Intern. Med. 27, 1113\u20131120. https:\/\/doi.org\/10.1111\/jvim.12159 (2013).","journal-title":"J. Vet. Intern. Med."},{"key":"45433_CR58","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1111\/jvim.12162","volume":"27","author":"FM Park","year":"2013","unstructured":"Park, F. M. et al. Hypercoagulability and ACTH-dependent hyperadrenocorticism in dogs. J. Vet. Intern. Med. 27, 1136\u20131142. https:\/\/doi.org\/10.1111\/jvim.12162 (2013).","journal-title":"J. Vet. Intern. Med."},{"key":"45433_CR59","doi-asserted-by":"publisher","first-page":"499","DOI":"10.2460\/javma.242.4.499","volume":"242","author":"T Higuchi","year":"2013","unstructured":"Higuchi, T. et al. Characterization and treatment of transitional cell carcinoma of the abdominal wall in dogs: 24 cases (1985\u20132010). J. Am. Vet. Med. Assoc. 242, 499\u2013506. https:\/\/doi.org\/10.2460\/javma.242.4.499 (2013).","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"45433_CR60","first-page":"906","volume":"9","author":"CJ Henry","year":"2003","unstructured":"Henry, C. J. et al. Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma. Clin. Cancer Res. 9, 906\u2013911 (2003).","journal-title":"Clin. Cancer Res."},{"key":"45433_CR61","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1111\/j.1939-1676.2011.00796.x","volume":"25","author":"EJ Arnold","year":"2011","unstructured":"Arnold, E. J. et al. Clinical trial of vinblastine in dogs with transitional cell carcinoma of the urinary bladder. J. Vet. Intern. Med. 25, 1385\u20131390. https:\/\/doi.org\/10.1111\/j.1939-1676.2011.00796.x (2011).","journal-title":"J. Vet. Intern. Med."},{"key":"45433_CR62","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/jvim.12013","volume":"27","author":"DW Knapp","year":"2013","unstructured":"Knapp, D. W. et al. Randomized trial of cisplatin versus firocoxib versus cisplatin\/firocoxib in dogs with transitional cell carcinoma of the urinary bladder. J. Vet. Intern. Med. 27, 126\u2013133. https:\/\/doi.org\/10.1111\/jvim.12013 (2013).","journal-title":"J. Vet. Intern. Med."},{"key":"45433_CR63","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3233\/BLC-200282","volume":"6","author":"T Strandgaard","year":"2020","unstructured":"Strandgaard, T. et al. Mutational analysis of field cancerization in bladder cancer. Bladder Cancer 6, 253\u2013264. https:\/\/doi.org\/10.3233\/BLC-200282 (2020).","journal-title":"Bladder Cancer"},{"key":"45433_CR64","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1476-5810.2005.00070.x","volume":"3","author":"PA Boria","year":"2005","unstructured":"Boria, P. A. et al. Carboplatin and piroxicam therapy in 31 dogs with transitional cell carcinoma of the urinary bladder. Vet. Comp. Oncol. 3, 73\u201380. https:\/\/doi.org\/10.1111\/j.1476-5810.2005.00070.x (2005).","journal-title":"Vet. Comp. Oncol."},{"key":"45433_CR65","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1939-1676.1994.tb03232.x","volume":"8","author":"DW Knapp","year":"1994","unstructured":"Knapp, D. W. et al. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J. Vet. Intern. Med. 8, 273\u2013278. https:\/\/doi.org\/10.1111\/j.1939-1676.1994.tb03232.x (1994).","journal-title":"J. Vet. Intern. Med."},{"key":"45433_CR66","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/vco.12344","volume":"16","author":"L Walters","year":"2018","unstructured":"Walters, L., Martin, O., Price, J. & Sula, M. M. Expression of receptor tyrosine kinase targets PDGFR-\u03b2, VEGFR2 and KIT in canine transitional cell carcinoma. Vet. Comp. Oncol. 16, 117\u2013122. https:\/\/doi.org\/10.1111\/vco.12344 (2018).","journal-title":"Vet. Comp. Oncol."},{"key":"45433_CR67","doi-asserted-by":"publisher","first-page":"243","DOI":"10.5326\/JAAHA-MS-6905","volume":"55","author":"TL Gustafson","year":"2019","unstructured":"Gustafson, T. L. & Biller, B. Use of toceranib phosphate in the treatment of canine bladder tumors: 37 cases. J. Am. Anim. Hosp. Assoc. 55, 243\u2013248. https:\/\/doi.org\/10.5326\/JAAHA-MS-6905 (2019).","journal-title":"J. Am. Anim. Hosp. Assoc."},{"key":"45433_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1515\/raon-2016-0006","volume":"50","author":"LG Campana","year":"2016","unstructured":"Campana, L. G. et al. Recommendations for improving the quality of reporting clinical electrochemotherapy studies based on qualitative systematic review. Radiol. Oncol. 50, 1\u201313. https:\/\/doi.org\/10.1515\/raon-2016-0006 (2016).","journal-title":"Radiol. Oncol."},{"key":"45433_CR69","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1016\/j.humpath.2012.01.008","volume":"43","author":"L Cheng","year":"2012","unstructured":"Cheng, L., MacLennan, G. T. & Lopez-Beltran, A. Histologic grading of urothelial carcinoma: A reappraisal. Hum. Pathol. 43, 2097\u20132108. https:\/\/doi.org\/10.1016\/j.humpath.2012.01.008 (2012).","journal-title":"Hum. Pathol."},{"key":"45433_CR70","first-page":"632","volume-title":"Tumor in Domestic Animals","author":"DJ Meuten","year":"2017","unstructured":"Meuten, D. J. & Meuten, L. K. Tumors of the urinary system. In Tumor in Domestic Animals 5th edn (eds Meuten, D. J. & Meuten, L. K.) 632\u2013688 (Wiley-Blackwell, 2017).","edition":"5"},{"key":"45433_CR71","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.2460\/javma.252.9.1073","volume":"252","author":"MA Giuffrida","year":"2018","unstructured":"Giuffrida, M. A., Brown, D. C., Ellenberg, S. S. & Farrar, J. T. Development and psychometric testing of the canine owner-reported quality of life questionnaire, an instrument designed to measure quality of life in dogs with cancer. J. Am. Vet. Med. Assoc. 252, 1073\u20131083. https:\/\/doi.org\/10.2460\/javma.252.9.1073 (2018).","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"45433_CR72","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026 (2009).","journal-title":"Eur. J. Cancer"},{"key":"45433_CR73","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.tvjl.2015.01.017","volume":"205","author":"CM Fulkerson","year":"2015","unstructured":"Fulkerson, C. M. & Knapp, D. W. Management of transitional cell carcinoma of the urinary bladder in dogs: A review. Vet. J. 205, 217\u2013225. https:\/\/doi.org\/10.1016\/j.tvjl.2015.01.017 (2015).","journal-title":"Vet. J."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-45433-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-45433-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-45433-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T13:10:34Z","timestamp":1701263434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-45433-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,29]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["45433"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-45433-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2658010\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,29]]},"assertion":[{"value":"5 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21078"}}